GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) is a China-based pharmaceutical company engaged in the research, development, production and sale of chemical drugs, biological products and medical devices. The company offers a range of core products including anti-infective drugs such as Sanli Su (clindamycin phosphate glucose injection), Sanli Kang (ornidazole sodium chloride injection) and azithromycin series; cardiovascular drugs like metoprolol tartrate injection; sterile powder injections including omeprazole sodium, pantoprazole sodium and ceftazidime; and other offerings such as ambroxol hydrochloride oral solution, medical devices and disinfectants. It operates primarily in the domestic Chinese market with manufacturing facilities in Guizhou province and distributes through hospitals, pharmacies and wholesalers. Founded in 2001 and headquartered in Guiyang, Guizhou, the company focuses on sterile preparations and has expanded its portfolio through consistent R&D investments. In recent developments, GuiZhou SanLi Pharmaceutical completed a major production base expansion in 2024 to boost capacity for high-end injections, received CFDA approval for new formulations of its flagship anti-infective products in early 2025, and formed strategic partnerships with regional distributors to enhance market penetration amid China's healthcare reforms.